Have a Certificate of Analysis we don't?
Drop it here. Anonymous by design — no account, no email, your IP is hashed weekly for abuse-prevention only. We OCR it, parse it, and add it to the corpus that powers every vendor page on this site. The long tail (Telegram-only sellers, niche OEMs) only gets covered if customers with skin in the game contribute one.
Submit a COA →Free tools
TitrateLab research
Original analysis and explainers from our own COA corpus — not third-party abstracts.
-
Does DSIP Actually Work? An Honest Evidence Review
Does DSIP actually work? The honest evidence read: tiny old studies (n=6-16), the best-controlled trial weak-to-negative, no receptor or gene in 49 years, and no modern RCTs. Research-use-only.
-
XTP Peptides Underfilled Its Retatrutide, Then Refused to Honor Its Own Guarantee
Between late May and June 2026, customer-commissioned independent lab tests on products from XTP (known in channels as Xi'an Taiye Chemical Co.) found a multi-product quality collapse: a Janoshik group test on its R30 retatrutide returned roughly 4mg of a labeled 30mg product in two of three vials, GHK-Cu underfilled by ~21mg, and Tesamorelin-10 below the vendor's own published refund threshold, which the vendor then refused to honor. This is a dated, source-linked account of what the certificates show, what buyers reported, and why none of it was in any aggregator until now.
-
CJC-1295 is the dirtiest peptide we test: 19% of vials fail purity (vs 0.2% for tirzepatide)
Across 269 third-party CJC-1295 assays in the TitrateLab corpus, nearly one in five tests below 90% purity — roughly 76× the failure rate of tirzepatide and 49× retatrutide. This is a dated, certificate-linked breakdown of which batches failed, by how much, and when, with every vendor claim sitting beside its own certificate of analysis. No editorializing beyond what the certificates show.
-
The Peptide Vendor Graveyard: every verified shutdown, exit scam, and FDA action 2018-2026
A dated, cited archive of every major enforcement action, vendor shutdown, lab controversy, and regulatory milestone in the research peptide grey market from 2018 through April 2026. Primary sources only. Updated as events happen. This is the canonical reference for "what happened to that vendor" — so you stop relying on Reddit rumors and forum memory.
-
The July 23 PCAC review could collapse the peptide grey market's core demand. Here's what's at stake.
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee meets to review whether BPC-157, TB-500, and ~12 other peptides should be restored to Category 1, a move HHS Secretary RFK Jr. announced on JRE #2461 back in February. If approved, compounding pharmacies could legally dispense these compounds for the first time since September 2023, and the grey-market moat that built Peptide Sciences, Amino Asylum, and the rest collapses. What the community needs to know before the vote.
-
HGH is discussed 88× more than it's tested. Here's what the 70 batches we have show.
Across a 19-month window, HGH appeared in 6,172 peptide-tagged Discord messages in our corpus. Our Certificate-of-Analysis database contains 70 HGH assays, substantially more than earlier versions of this article after a MESO-Rx analytical-lab subforum crawl and Janoshik public-portal backfill. The 88× gap between how much people discuss it and how much anyone verifies it is still the largest testing gap of any compound we track. Here's what the 70 batches show, and why HGH remains the hardest compound on this market to actually verify.
-
The peptide grey market collapsed in 9 months. Quality got dramatically better at the same time.
Between June 2025 and March 2026 the research-peptide grey market lost its three biggest players: Amino Asylum to an FDA raid, Science.bio to voluntary closure, and Peptide Sciences to a regulatory reversal. We measured what happened to quality across 8,452 tested batches from 294 manufacturers, and the story nobody is telling is that purity went up.
Latest indexed studies
Browse all 5380 studies →- Pumicyclin A, a novel circular bacteriocin from *Bacillus pumilus*, shows broad-spectrum activity against Gram-positive foodborne pathogens
- Review Maps Strategies to Mitigate Goat's Milk Casein Allergenicity for Hypoallergenic Infant Formulas
- Fusarium graminearum orchestrates three-phase virulence cascade for progressive maize root rot
- Review Unpacks Gut Microbiome-Endocrine Axis, Detailing Microbial Metabolite Impact on Obesity and Therapeutic Strategies
- Comprehensive review highlights `Acinetobacter baumannii` resistance mechanisms, emerging therapies including antimicrobial peptides, and vaccine development challenges
- Engineered W20-LT fusion protein ameliorates cognitive deficits and amyloid pathology in Alzheimer's mice
- Lep5 R8-18, a modified scorpion peptide, enhances antibacterial activity, reduces hemolysis.
- CREBZF/c-Jun complex regulates ApoE expression, reducing cholesterol and influencing female steroidogenesis.
- Semaglutide's Multi-Organ Benefits in Type 2 Diabetes Stem from Broad Molecular Adaptations Across Inflammatory, Lipid, and ECM Pathways
- Repurposed ramipril, carvedilol, metformin, and generic statins offer low-cost, high-impact cardiovascular prevention
- Norditropin® lyophilized and liquid somatropin formulations undergo safety evaluation in children with growth hormone deficiency
- Nurse Home-Visiting Program's Long-Term Impact on Offspring Chronic Disease Risk Explored in Longitudinal Cohort
Browse by peptide
- Semaglutide · 691
- Insulin · 529
- Tirzepatide · 512
- Liraglutide · 303
- THYMOSIN-ALPHA-1 · 147
- Retatrutide · 134
- LL-37 · 117
- IGF-1 · 108
- Mots-c · 108
- BPC-157 · 107
- GHRP-6 · 105
- MK-677 · 95
- GHRP-2 · 92
- Ghk-cu · 91
- Sermorelin · 89
- SS-31 · 86
- Epitalon · 81
- Melanotan-ii · 80
- Mgf · 77
- Selank · 74
- Semax · 72
- Cagrilintide · 68
- PT-141 · 68
- Oxytocin · 56
- Hgh · 45
- Ipamorelin · 45
- Dulaglutide · 40
- Humanin · 37
- Nad · 37
- Survodutide · 37